{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:20:08Z","timestamp":1779916808081,"version":"3.53.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Allergan Canada Inc."},{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00415-018-8819-6","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T07:07:11Z","timestamp":1521529631000},"page":"1269-1278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance"],"prefix":"10.1007","volume":"265","author":[{"given":"Olivia","family":"Samotus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandar","family":"Jog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"8819_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00415-014-7586-2","volume":"262","author":"C Comella","year":"2015","unstructured":"Comella C, Bhatia K (2015) An international survey of patients with cervical dystonia. J Neurol 262:837\u2013848","journal-title":"J Neurol"},{"issue":"2","key":"8819_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/mdc3.12238","volume":"3","author":"ES Molho","year":"2016","unstructured":"Molho ES, Stacy M, Gillard P et al (2016) Impact of cervical dystonia on work productivity: an analysis from a patient registry. Mov Disord Clin Pract 3(2):130\u2013138","journal-title":"Mov Disord Clin Pract"},{"key":"8819_CR3","first-page":"77","volume-title":"Neurologic clinics","author":"HA Jinnah","year":"2015","unstructured":"Jinnah HA, Factor S (2015) Diagnosis and treatment of dystonia. In: Jankovic J (ed) Neurologic clinics. Elsevier, Amsterdam, pp 77\u2013100"},{"key":"8819_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","volume":"18","author":"A Albanese","year":"2011","unstructured":"Albanese A, Asmus F, Bhatia KP et al (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18:5\u201318. \n                    https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03042.x","journal-title":"Eur J Neurol"},{"key":"8819_CR5","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A et al (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment Subcommittee of the American Academy of Neurology. Neurology 70:1699\u20131706. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000311389.26145.95","journal-title":"Neurology"},{"issue":"Suppl 1","key":"8819_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0733-8619(08)80005-9","volume":"26","author":"D Swope","year":"2008","unstructured":"Swope D, Barbano R (2008) Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin 26(Suppl 1):54\u201365. \n                    https:\/\/doi.org\/10.1016\/S0733-8619(08)80005-9","journal-title":"Neurol Clin"},{"issue":"165","key":"8819_CR7","first-page":"1","volume":"7","author":"MF Contarino","year":"2016","unstructured":"Contarino MF, Smit M, Van den Dool J, Volkmann J, Tijssen MAJ (2016) Unmet needs in the management of cervical dystonia. Front Neurol 7(165):1\u20137","journal-title":"Front Neurol"},{"key":"8819_CR8","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00415-015-7703-x","volume":"262","author":"A Albanese","year":"2015","unstructured":"Albanese A, Abbruzzese G, Dressler D, Duzynski W, Khatkova S, Marti MJ et al (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol 262:2201\u20132213","journal-title":"J Neurol"},{"issue":"1\u20132","key":"8819_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2014.12.030","volume":"349","author":"J Jankovic","year":"2015","unstructured":"Jankovic J, Adler CH, Charles D et al (2015) Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci 349(1\u20132):84\u201393","journal-title":"J Neurol Sci"},{"key":"8819_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2017.02.042","volume":"376","author":"RM Trosch","year":"2017","unstructured":"Trosch RM, Espay AJ, Truong D et al (2017) Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: the ANCHOR-CD registry. J Neurol Sci 376:84\u201390","journal-title":"J Neurol Sci"},{"key":"8819_CR11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s00415-016-8136-x","volume":"263","author":"HA Jinnah","year":"2016","unstructured":"Jinnah HA, Goodmann E, Rosen AR, Evatt M, Freeman A, Factor S (2016) Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol 263:1188\u20131194","journal-title":"J Neurol"},{"issue":"5","key":"8819_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.parkreldis.2013.01.018","volume":"19","author":"SW Nijmeijer","year":"2013","unstructured":"Nijmeijer SW, Koelman JH, Standaar TS, Postma M, Tijssen MA (2013) Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography. Parkinsonism Relat Disord 19(5):533\u2013538","journal-title":"Parkinsonism Relat Disord"},{"key":"8819_CR13","first-page":"1","volume":"2","author":"V Evidente","year":"2014","unstructured":"Evidente V, Pappert EJ (2014) Botulinum toxin therapy for cervical dystonia: the science of dosing. Tremor and Other Hyperkin Mov 2:1\u201310","journal-title":"Tremor and Other Hyperkin Mov"},{"key":"8819_CR14","first-page":"CD003633","volume":"12","author":"M Castel\u00e3o","year":"2017","unstructured":"Castel\u00e3o M, Marques RE, Duarte GS et al (2017) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 12:CD003633","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"8819_CR15","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","volume":"120","author":"VG Evidente","year":"2013","unstructured":"Evidente VG, Fernandez HH, Ledoux MS et al (2013) A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(\u00ae) in cervical dystonia. J Neural Transm (Vienna) 120(12):1699\u20131707","journal-title":"J Neural Transm (Vienna)"},{"issue":"1\u20132","key":"8819_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jns.2015.03.047","volume":"352","author":"E Bruijn De","year":"2015","unstructured":"De Bruijn E, Nijmeijer SWR, Forbes PA et al (2015) Improved identification of dystonic cervical muscles via abnormal muscle activity during isometric contractions. J of Neurol Sci 352(1\u20132):10\u201316","journal-title":"J of Neurol Sci"},{"issue":"1","key":"8819_CR17","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1186\/s40064-016-2967-x","volume":"5","author":"C Wu","year":"2016","unstructured":"Wu C, Xue F, Chang W (2016) Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia. SpringerPlus 5(1):1292\u20131296","journal-title":"SpringerPlus"},{"key":"8819_CR18","first-page":"1","volume":"5","author":"F Rahimi","year":"2015","unstructured":"Rahimi F, Samotus O, Lee J, Jog MS (2015) Effective management of upper limb parkinsonian tremor by IncobotulinumtoxinA injections using sensor-based biomechanical patterns. Tremor and Other Hyperkin Mov 5:1\u201313","journal-title":"Tremor and Other Hyperkin Mov"},{"issue":"4","key":"8819_CR19","doi-asserted-by":"publisher","first-page":"e0153739","DOI":"10.1371\/journal.pone.0153739","volume":"11","author":"O Samotus","year":"2016","unstructured":"Samotus O, Rahimi F, Lee J, Jog M (2016) Functional ability improved in essential tremor by IncobotulinumtoxinA injections using kinematically determined biomechanical patterns\u2014a new future. PLoS One 11(4):e0153739","journal-title":"PLoS One"},{"issue":"1\u20132","key":"8819_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","volume":"308","author":"CL Comella","year":"2011","unstructured":"Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 308(1\u20132):103\u2013109","journal-title":"J Neurol Sci"},{"issue":"1","key":"8819_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/PL00007848","volume":"249","author":"M Naumann","year":"2002","unstructured":"Naumann M, Yakovleff A, Durif F (2002) A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 249(1):57\u201363","journal-title":"J Neurol"},{"issue":"6","key":"8819_CR22","doi-asserted-by":"publisher","first-page":"e0178670","DOI":"10.1371\/journal.pone.0178670","volume":"12","author":"O Samotus","year":"2017","unstructured":"Samotus O, Lee J, Jog M (2017) Long- term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS One 12(6):e0178670","journal-title":"PLoS One"},{"issue":"6","key":"8819_CR23","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/mds.25739","volume":"29","author":"SD Kim","year":"2014","unstructured":"Kim SD, Yiannikas C, Mahant N, Vucic S, Fung VSC (2014) Treatment of proximal upper limb tremor with botulinum toxin therapy. Mov Disord 29(6):835\u2013838","journal-title":"Mov Disord"},{"key":"8819_CR24","unstructured":"Botox [Package Insert] 2010. Allergan Pharmaceuticals, Irvine, CA"},{"key":"8819_CR25","first-page":"1","volume":"0","author":"MH Marion","year":"2016","unstructured":"Marion MH, Humberstone M, Grunewald R, Wimalaratna S (2016) British neurotoxin network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin. Prac Neurol 0:1\u20138","journal-title":"Prac Neurol"},{"key":"8819_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2017.09.004","author":"HA Jinnah","year":"2017","unstructured":"Jinnah HA, Comella CL, Perlmutter J, Lungu C, Hallett M, Investigators Dystonia Coalition (2017) Longitudinal studies of botulinum toxin in cervical dystonia: why do patients discontinue therapy? Toxicon. \n                    https:\/\/doi.org\/10.1016\/j.toxicon.2017.09.004\n                    \n                   (pii: S0041-0101(17)30277-5)","journal-title":"Toxicon"},{"issue":"11","key":"8819_CR27","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/mds.26384","volume":"30","author":"A Albanese","year":"2015","unstructured":"Albanese A, Romito LM, Calandrella D (2015) Therapeutic advances in dystonia. Mov Disord 30(11):1547\u20131556","journal-title":"Mov Disord"},{"issue":"8","key":"8819_CR28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.27072","volume":"32","author":"J Jankovic","year":"2017","unstructured":"Jankovic J (2017) Botulinum toxin: state of the art. Mov Disord 32(8):1131\u20131138","journal-title":"Mov Disord"},{"issue":"11","key":"8819_CR29","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.clinph.2011.04.012","volume":"122","author":"L Werdelin","year":"2011","unstructured":"Werdelin L, Dalager T, Fuglsang-Frederiksen A (2011) The utility of EMG interference pattern analysis in botulinum toxin treatment of torticollis: a randomised, controlled and blinded study. Clin Neurophysiol 122(11):2305\u20132309","journal-title":"Clin Neurophysiol"},{"key":"8819_CR30","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/1097-4598(200011)23:11<1752::AID-MUS12>3.0.CO;2-U","volume":"23","author":"JA Gerpen Van","year":"2000","unstructured":"Van Gerpen JA, Matsumoto JY, Ahlskog JE, Maraganore DM, McManis PG (2000) Utility of an EMG mapping study in treating cervical dystonia. Muscle Nerve 23:1752\u20131756","journal-title":"Muscle Nerve"},{"key":"8819_CR31","doi-asserted-by":"publisher","unstructured":"Kilbane C, Ostrem J, Galifianakis N, Grace J, Markun L, Glass GA (2012) Multichannel electromyographic mapping to optimize OnabotulinumtoxinA efficacy in cervical dystonia. Tremor Other Hyperkinet Mov (N.Y.) 2. pii: tre-02-91-598-1. \n                    https:\/\/doi.org\/10.7916\/D8XK8D8V","DOI":"10.7916\/D8XK8D8V"},{"issue":"6","key":"8819_CR32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1212\/WNL.0000000000003596","volume":"88","author":"S Pirio richardson","year":"2017","unstructured":"Pirio richardson S, Wegele AR, Skipper B, Deligtisch A, Jinnah HA (2017) Dystonia treatment: patterns of medication use in an international cohort. Neurology 88(6):543\u2013550","journal-title":"Neurology"},{"key":"8819_CR33","unstructured":"Jog M, Lee J, Althaus M, Scheschonka A, Dersch H, E. T. Study Team, Simpson D (2017) Efficacy and safety of incobotulinumtoxinA (inco\/A) for essential tremor using kinematics-guided clinical decision support: a randomized, double-blind, placebo-controlled trial [abstract]. Mov Disord 32(suppl 2). \n                    http:\/\/www.mdsabstracts.org\/abstract\/efficacy-and-safety-of-incobotulinumtoxina-incoa-for-essential-tremor-using-kinematics-guided-clinical-decision-support-a-randomized-double-blind-placebo-controlled-trial\/\n                    \n                  . Accessed on October 4 2017"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-8819-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8819-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8819-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T20:21:00Z","timestamp":1553026860000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-8819-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["8819"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-8819-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"22 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study reported in this manuscript has been approved by the Western University Health Sciences Research Ethics Board (REB) and have, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study were omitted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Dr. Jog reports a research grant from Allergan Canada Inc., during the conduct of the study. Outside of the study, Dr. Jog also is a scientific advisor and receives financial support from AbbVie, Allergan Inc., Boston Scientific, Ipsen, MDDT Inc., Medtronic, Merz Pharma, Novartis, and Teva Pharmaceuticals. In addition, Dr. Jog has two patents PCT\/CA2013\/000804 and PCT\/CA2014\/050893 pending that are assigned to MDDT Inc. Mr. Lee is a former research associate and is currently a MDDT Inc. employee and a shareholder along with Dr. Jog. MDDT Inc. is a startup commercializing a diagnostic technology. Ms. Samotus reports a government-industry grant from MITACS during the conduct of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}